TY - JOUR
T1 - Physicians' human papillomavirus vaccine recommendations, 2009 and 2011
AU - Vadaparampil, Susan T.
AU - Malo, Teri L.
AU - Kahn, Jessica A.
AU - Salmon, Daniel A.
AU - Lee, Ji Hyun
AU - Quinn, Gwendolyn P.
AU - Roetzheim, Richard G.
AU - Bruder, Karen L.
AU - Proveaux, Tina M.
AU - Zhao, Xiuhua
AU - Halsey, Neal A.
AU - Giuliano, Anna R.
N1 - Funding Information:
Anna R. Giuliano has received funding from Merck for consultancy and lectures and receives grant funding from Merck and GlaxoSmithKline.
Funding Information:
This research was supported by a grant from the NIH ( R01AI076440-01 ). The NIH played no role in the design or conduct of the study; in collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the paper. The work contained within this publication was supported in part by the Survey Methods Core Facility at the Moffitt Cancer Center.
PY - 2014/1
Y1 - 2014/1
N2 - Background Physician recommendation is a key predictor of human papillomavirus (HPV) vaccine uptake. Understanding factors associated with recommendation is important for efforts to increase current suboptimal vaccine uptake. Purpose This study aimed to examine physician recommendations to vaccinate female patients aged 11-26 years, in 2009 and 2011, at 3 and 5 years postvaccine licensure, respectively. A second aim was to identify trends in factors associated with vaccine recommendation for ages 11 and 12 years. Methods Nationally representative samples of physicians practicing family medicine, pediatrics, and obstetrics and gynecology were randomly selected from the American Medical Association Physician Masterfile (n=1538 in 2009, n=1541 in 2011). A mailed survey asked physicians about patient and clinical practice characteristics; immunization support; and frequency of HPV vaccine recommendation ("always" ≥75% of the time vs other). Analyses were conducted in 2012. Results Completed surveys were received from 1013 eligible physicians (68% response rate) in 2009 and 928 (63%) in 2011. The proportion of physicians who reported always recommending HPV vaccine increased significantly from 2009 to 2011 for patients aged 11 or 12 years (35% vs 40%, respectively; p=0.03), but not for patients aged 13-17 years (53% vs 55%; p=0.28) or 18-26 years (50% vs 52%; p=0.52). Physician specialty, age, and perceived issues/barriers to vaccination were associated with vaccine recommendation for patients aged 11 or 12 in both years. Conclusions Results suggest a modest increase in recommendations for HPV vaccination of girls aged 11 or 12 years over a 2-year period; however, recommendations remain suboptimal for all age groups despite national recommendations for universal immunization.
AB - Background Physician recommendation is a key predictor of human papillomavirus (HPV) vaccine uptake. Understanding factors associated with recommendation is important for efforts to increase current suboptimal vaccine uptake. Purpose This study aimed to examine physician recommendations to vaccinate female patients aged 11-26 years, in 2009 and 2011, at 3 and 5 years postvaccine licensure, respectively. A second aim was to identify trends in factors associated with vaccine recommendation for ages 11 and 12 years. Methods Nationally representative samples of physicians practicing family medicine, pediatrics, and obstetrics and gynecology were randomly selected from the American Medical Association Physician Masterfile (n=1538 in 2009, n=1541 in 2011). A mailed survey asked physicians about patient and clinical practice characteristics; immunization support; and frequency of HPV vaccine recommendation ("always" ≥75% of the time vs other). Analyses were conducted in 2012. Results Completed surveys were received from 1013 eligible physicians (68% response rate) in 2009 and 928 (63%) in 2011. The proportion of physicians who reported always recommending HPV vaccine increased significantly from 2009 to 2011 for patients aged 11 or 12 years (35% vs 40%, respectively; p=0.03), but not for patients aged 13-17 years (53% vs 55%; p=0.28) or 18-26 years (50% vs 52%; p=0.52). Physician specialty, age, and perceived issues/barriers to vaccination were associated with vaccine recommendation for patients aged 11 or 12 in both years. Conclusions Results suggest a modest increase in recommendations for HPV vaccination of girls aged 11 or 12 years over a 2-year period; however, recommendations remain suboptimal for all age groups despite national recommendations for universal immunization.
UR - http://www.scopus.com/inward/record.url?scp=84890835907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890835907&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2013.07.009
DO - 10.1016/j.amepre.2013.07.009
M3 - Article
C2 - 24355675
AN - SCOPUS:84890835907
SN - 0749-3797
VL - 46
SP - 80
EP - 84
JO - American journal of preventive medicine
JF - American journal of preventive medicine
IS - 1
ER -